Bulletin
Investor Alert

Market Pulse Archives

Oct. 15, 2019, 11:26 a.m. EDT

Relmada Therapeutics stock rockets 137% on positive trial of depression treatment

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Relmada Therapeutics Inc. (RLMD)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Relmada Therapeutics Inc. shares /zigman2/quotes/200762009/composite RLMD -1.57% soared 137% Tuesday, after the clinical-stage biotech reported positive results from a midstage trial of a treatment for depression. New York-based Relmada said the Phase 2 trial of REL-1017 showed statistically significant improvement for patients suffering from treatment resistant depression versus placebo. "We are very pleased to announce these highly compelling results," said Dr. Ottavio Vitolo, Relmada head of R&D and CMO. "This is the first clinical evidence that REL-1017 exerts a rapid and robust antidepressant effect, which continues even after treatment discontinuation." REL-1017, or dextromethadone, is a rapidly acting oral agent that works as an NMDA receptor antagonist and on the same binding site as ketamine, but without the side effects that are associated with ketamine. The U.S. Food and Drug Administration has granted the drug fast track designation. Shares have gained 476% in 2019, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.77% has gained 19%.

/zigman2/quotes/200762009/composite
US : U.S.: Nasdaq
$ 25.10
-0.40 -1.57%
Volume: 48,231
Nov. 15, 2019 3:59p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$258.36 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,120.46
+23.83 +0.77%
Volume: 1.87B
Nov. 15, 2019 5:04p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.